Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TYK Medicines, Inc. Class H ( (HK:2410) ) has shared an announcement.
TYK Medicines has announced that China’s National Medical Products Administration has accepted its New Drug Application for Asandeutertinib (TY-9591), a deuterated analog of osimertinib intended as a first-line treatment for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer with central nervous system metastases. Backed by Phase I and II clinical data indicating superior intracranial and systemic response rates and clinical benefit compared with existing therapy osimertinib, the filing underscores TYK Medicines’ ambition to strengthen its position in targeted lung cancer treatments, although the company cautions that acceptance of the application is only an administrative step and approval is not guaranteed, highlighting the inherent risks and uncertainties in pharmaceutical development for investors and other stakeholders.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc. is a China-based biopharmaceutical company focused on the research and development of innovative, high-tech drugs. The company specializes in oncology therapies, particularly targeted treatments for lung cancer driven by EGFR mutations, and aims to address significant unmet clinical needs in both systemic and central nervous system disease control.
Average Trading Volume: 2,994,078
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.64B
Learn more about 2410 stock on TipRanks’ Stock Analysis page.